Your browser doesn't support javascript.
loading
Yin Yang 1 expression predicts a favourable survival in diffuse large B-cell lymphoma.
Xue, Tian; Lin, Jia-Xin; He, Ya-Qi; Li, Ji-Wei; Liu, Ze-Bing; Jia, Yi-Jun; Zhou, Xiao-Yan; Li, Xiao-Qiu; Yu, Bao-Hua.
Affiliation
  • Xue T; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Lin JX; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • He YQ; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Li JW; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Liu ZB; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Jia YJ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Zhou XY; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Li XQ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Yu BH; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Heliyon ; 10(2): e24376, 2024 Jan 30.
Article in En | MEDLINE | ID: mdl-38312674
ABSTRACT

Aims:

Yin Yang 1 (YY1) is a multifunctional transcription factor that plays an important role in tumour development and progression, while its clinical significance in diffuse large B-cell lymphoma (DLBCL) remains largely unexplored. This study aimed to investigate the expression and clinical implications of YY1 in DLBCL.

Methods:

YY1 expression in 198 cases of DLBCL was determined using immunohistochemistry. The correlation between YY1 expression and clinicopathological parameters as well as the overall survival (OS) and progression-free survival (PFS) of patients was analyzed.

Results:

YY1 protein expression was observed in 121 out of 198 (61.1 %) DLBCL cases. YY1 expression was significantly more frequent in cases of the GCB subgroup than in the non-GCB subgroup (P = 0.005). YY1 was positively correlated with the expression of MUM1, BCL6, pAKT and MYC/BCL2 but was negatively associated with the expression of CXCR4. No significant relationships were identified between YY1 and clinical characteristics, including age, sex, stage, localization, and B symptoms. Univariate analysis showed that the OS (P = 0.003) and PFS (P = 0.005) of patients in the YY1-negative group were significantly worse than those in the YY1-positive group. Multivariate analysis indicated that negative YY1 was a risk factor for inferior OS (P < 0.001) and PFS (P = 0.017) independent of the international prognostic index (IPI) score, treatment and Ann Arbor stage. Furthermore, YY1 is more powerful for stratifying DLBCL patients into different risk groups when combined with MYC/BCL2 double-expression (DE) status.

Conclusions:

YY1 was frequently expressed in DLBCL, especially in those of GCB phenotype and with MYC/BCL2-DE. As an independent prognostic factor, YY1 expression could predict a favourable outcome in DLBCL. In addition, a complex regulatory mechanism might be involved in the interactions between YY1 and MYC, pAKT as well as CXCR4 in DLBCL, which warrants further investigation.
Key words

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Heliyon Year: 2024 Type: Article Affiliation country: China

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Heliyon Year: 2024 Type: Article Affiliation country: China